EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Yishenyangsui granule for degenerative cervical myelopathy: a randomized, double-blind, placebo-controlled trial with long-term follow-up

He Yin, Xin Chen, Zhiwei Liu, Bo Xu, Zhefeng Jin, Yan Liu, Baoyu Qi, Bin Tang, Ping Wang, Fanping Xu, Xu Wei, Jie Yu und 1 weitere

Frontiers in Pharmacology · 31.01.2025 · 16

DOI: 10.3389/fphar.2025.1542231 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 31.01.2025. Verfasst von He Yin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This randomized controlled trial aims to evaluate the efficacy and safety of Yishenyangsui granule for treating Degenerative Cervical Myelopathy. Materials and methods A randomized, double-blind, placebo-controlled clinical trial was conducted with 152 participants recruited from three centers and randomly assigned to receive either Yishenyangsui granule or placebo. The Japanese Orthopaedic Association (JOA) score and Neck Disability Index (NDI) score were evaluated for 32 weeks. Patient-reported outcomes including surgical treatment data, re-treatment data, and patient-reported condition were collected for long-term follow-up. This trial was approved by the ethics committee of WangJing Hospital of China Academy of Chinese Medical Sciences (WJEC-KT-2016-004-P001) and was registered at the Chinese Clinical Trials Registry (ChiCTR-INR-16009723) on 03 November 2016 (Check out at https://www.chictr.org.cn/indexEN.html for a more comprehensive overview).

Results

The results showed that the improvement in JOA score at week 8 was significantly better in the Yishenyangsui granule group than in the placebo group (1.47 vs. 0.43; P < 0.001). Furthermore, improvements in motor function of upper/lower extremities, sensory function of upper extremities, reading ability, and recreation domain scores were also significantly superior in the Yishenyangsui granule group compared to the placebo group (P < 0.05). Long-term follow-up outcomes revealed no statistical differences between groups regarding surgical treatment data or patient-reported condition (P > 0.05). However, there was a significant difference detected in re-treatment data between groups with a lower rate observed among those receiving Yishenyangsui granule compared to those receiving placebo [25 (43.10%) vs. 40 (68.97%); P = 0.033], indicating its effectiveness for treating mild-to-moderate Degenerative Cervical Myelopathy.

Conclusion

Yishenyangsui granule was effective in treating mild to moderate Degenerative Cervical Myelopathy. The participants have improved long-term outcomes. Clinical Trials Registration https://www.chictr.org.cn/indexEN.html , identifier ChiCTR-INR-16009723.

Schlagwörter

Stichwörter der Autor:innen

Chinese botanical drugscervical spondylotic myelopathydegenerative cervical myelopathylong-term follow-upnon-surgical treatment

Autor:innen und Institutionen

  • Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
  • Spine Department, Zhangjiakou Hospital of Traditional Chinese Medicine, Zhangjiakou City, Hebei, China.
  • Key Laboratory of Chinese Internal Medicine of Ministry of Education, Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital, Beijing, China.
  • First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
  • Spine Department, Beijing Hospital of Traditional Chinese Medicine, Beijing, China.
  • Beijing Key Laboratory of Manipulative Technique, Beijing, China.

Zitieren

APA

Yin, H., Chen, X., Liu, Z., Xu, B., Jin, Z., Liu, Y., Qi, B., Tang, B., Wang, P., Xu, F., Wei, X., Yu, J., & Zhu, L. (2025). Yishenyangsui granule for degenerative cervical myelopathy: a randomized, double-blind, placebo-controlled trial with long-term follow-up. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1542231

Vancouver

Yin H, Chen X, Liu Z, Xu B, Jin Z, Liu Y, et al. Yishenyangsui granule for degenerative cervical myelopathy: a randomized, double-blind, placebo-controlled trial with long-term follow-up. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1542231

BibTeX
@article{Yin2025,
  author = {Yin, He and Chen, Xin and Liu, Zhiwei and Xu, Bo and Jin, Zhefeng and Liu, Yan and Qi, Baoyu and Tang, Bin and Wang, Ping and Xu, Fanping and Wei, Xu and Yu, Jie and Zhu, Liguo},
  title = {Yishenyangsui granule for degenerative cervical myelopathy: a randomized, double-blind, placebo-controlled trial with long-term follow-up},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1542231}
}
Kostenlos starten →